Biotech RadarJobs updated

COMPANY

Kashiv BioSciences

kashivbiosciences.com ↗ · Mid-Atlantic

Status: Acquired, now part of Amneal Pharmaceuticals · How status works

New owner: Acquired by Amneal Pharmaceuticals (closed on or before 2026-08-10) · source (Aug 10, 2026) · Ownership changes

Clinical Phase 3

5 open jobs · last seen Oct 22, 2026 · 14 sources

Profile checked Oct 10, 2026

Keywords: Febrile Neutropenia Chronic Idiopathic Urticaria Metastatic Breast Cancer KSHN001034 TPI-120 with On body injector ADL-018 Autoinjector ADL-018

5Open jobs9Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Environmental Health and Safety - Senior ManagerKashiv BioSciences - PiscatawaySep 15, 2026Oct 16, 2026
Utility Operator / MechanicKashiv BioSciences - PiscatawaySep 2, 2026Oct 16, 2026
Quality Assurance (MQA) Specialist I - 2nd ShiftKashiv BioSciences - ChicagoAug 28, 2026Oct 16, 2026
Manufacturing QMS SupervisorKashiv BioSciences - PiscatawayAug 25, 2026Oct 16, 2026
External Manufacturing Operations (EMO), Senior ManagerKashiv BioSciences - PiscatawayAug 19, 2026Oct 16, 2026

See all 5 jobs

Timeline

  1. Partnership Partnership / licensing announced Feb 9, 2026. Source: company release on GlobeNewswire. source ↗
  2. Raise Private equity round: amount not published, announced Dec 22, 2025. Source: company release on GlobeNewswire. source ↗
  3. Partnership Partnership / licensing announced Sep 11, 2025. Source: company release on GlobeNewswire. source ↗
  4. Trial start Phase 1: Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KSHN001034 in Healthy Postmenopausal Female Volunteers source ↗
  5. Partnership Partnership / licensing announced Aug 5, 2025. Source: company release on GlobeNewswire. source ↗
  6. Trial start Phase 1: Pharmacokinetic, Immunogenicity, and Safety Evaluation of Pegfilgrastim TPI-120 in Healthy Adults source ↗
  7. Debt Debt: $150M (not counted as a raise), announced Apr 3, 2025. Source: company release on GlobeNewswire. source ↗
  8. Trial start Phase 1: A Comparative Pharmacokinetic Study of ADL-018 Autoinjector Compared to A Pre-filled Syringe in Healthy Subjects. source ↗
  9. Trial start Phase 1: A Comparative Evaluation of Pharmacokinetics and Immunogenicity. source ↗
  10. Trial start Phase 1: Open Label , Randomized, Three Arm Parallel Group Single Dose Comparative Pharmacokinetic , Safety and Immunogenicity Study in Healthy Subjects source ↗
  11. Trial start Phase 3: Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria source ↗
  12. Trial start Phase 1: Open Label, Sequential Dosing , Single Ascending Dose and Multiple Dose Safety Tolerability and Pharmacokinetic Study source ↗
  13. Trial start Phase 1: PK, PD, Safety & Immunogenicity of ADL-018 Lyo in Healthy Adult Subjects source ↗
  14. Trial start Phase 1: To Compare the PK, PD, Safety & Immunogenicity of ADL-018 in Healthy Subjects source ↗

Funding

Raised: amount not published · Debt: $150.0M. Last 2 years.

Clinical trials (lead sponsor) 9

RecordTitlePhaseStatusStartPrimary completion
NCT06929039Open Label , Randomized, Three Arm Parallel Group Single Dose Comparative Pharmacokinetic , Safety and Immunogenicity Study in Healthy SubjectsPhase 1CompletedJul 4, 2024Oct 16, 2024 (actual)
NCT06918587A Comparative Evaluation of Pharmacokinetics and Immunogenicity.Phase 1CompletedSep 5, 2024May 25, 2025 (actual)
NCT06929052A Comparative Pharmacokinetic Study of ADL-018 Autoinjector Compared to A Pre-filled Syringe in Healthy Subjects.Phase 1CompletedJan 29, 2025Aug 15, 2025 (actual)
NCT07416955Pharmacokinetic, Immunogenicity, and Safety Evaluation of Pegfilgrastim TPI-120 in Healthy AdultsPhase 1CompletedApr 5, 2025Oct 10, 2025 (actual)
NCT06995482Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KSHN001034 in Healthy Postmenopausal Female VolunteersPhase 1RecruitingAug 18, 20252026-05 (estimated)
NCT05774639Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic UrticariaPhase 3CompletedAug 15, 2023Oct 3, 2024 (actual)
NCT05564611PK, PD, Safety & Immunogenicity of ADL-018 Lyo in Healthy Adult SubjectsPhase 1CompletedNov 4, 2022Jul 30, 2023 (actual)
NCT06074757Open Label, Sequential Dosing , Single Ascending Dose and Multiple Dose Safety Tolerability and Pharmacokinetic StudyPhase 1CompletedMar 1, 2023Sep 10, 2023 (actual)
NCT05413161To Compare the PK, PD, Safety & Immunogenicity of ADL-018 in Healthy SubjectsPhase 1CompletedJul 7, 2022Feb 21, 2023 (actual)

Open jobs 5

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Environmental Health and Safety - Senior ManagerKashiv BioSciences - PiscatawaySep 15, 2026Oct 16, 2026Senior
Utility Operator / MechanicKashiv BioSciences - PiscatawaySep 2, 2026Oct 16, 2026Entry
Quality Assurance (MQA) Specialist I - 2nd ShiftKashiv BioSciences - ChicagoAug 28, 2026Oct 16, 2026Entry
Manufacturing QMS SupervisorKashiv BioSciences - PiscatawayAug 25, 2026Oct 16, 2026Senior
External Manufacturing Operations (EMO), Senior ManagerKashiv BioSciences - PiscatawayAug 19, 2026Oct 16, 2026Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Feedback